ArticleJournal of thrombosis and thrombolysis2026
Treatment failure in patients with obesity with venous thromboembolism receiving truncated vs. recommended lead-in times with apixaban at an academic medical center.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal lead-in duration of apixaban following a period of therapeutic parenteral anticoagulation for venous thromboembolism (VTE) has become controversial, and truncated lead-in periods accounting for parenteral therapy have been proposed in recent studies. Results from previous studies cannot be generalized to many subpopulations of interest, including patients with obesity. This study characterized recurrent VTE in patients with obesity within 6 months of apixaban initiation based on full versus truncated lead-in times following parenteral anticoagulation. This single-center, multi-site, retrospective cohort study within the West Virginia University Medicine enterprise among adult patients with obesity, defined as body mass index (BMI) of 30 kg/m
Indexed as
Identifiers
40952588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.